Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05148533

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors

Sponsor: TJ Biopharma Co., Ltd.

Conditions Advanced Solid Tumor

Interventions TJ1133 Injection

Updated 8 times since 2022 Last updated: Apr 11, 2024 Started: Dec 30, 2021 Primary completion: Feb 3, 2023 Completion: Feb 3, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company Development strategy adjustment

Other terminated trials from TJ Biopharma Co., Ltd.

More terminations from TJ Biopharma Co., Ltd.

Other Advanced Solid Tumor trials with similar outcome

Browse all Advanced Solid Tumor trials

Listed as NCT05148533, this PHASE1/PHASE2 trial focuses on Advanced Solid Tumor and remains terminated or withdrawn. Sponsored by TJ Biopharma Co., Ltd., it has been updated 8 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Mar 2023 — May 2024 [monthly]

Terminated PHASE1_PHASE2

Status: Recruiting → Terminated

▶ Show 3 earlier versions

Sep 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2022 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TJ Biopharma Co., Ltd.

Data source: TJ Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bengbu, China , Changchun, China , Changsha, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China , Jinan, China and 5 more locations